The impact of proton pump inhibitors on bone regeneration and implant osseointegration

References

• Actis L, Gaviria L, Guda T, Ong JL. 2013. Antimicrobial surfaces for craniofacial implants: state of the art. J Korean Assoc Oral Maxillofac Surg. 39:43–54.
   PubMedGoogle Scholar
• Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ. 2014. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann Epidemiol. 24:286–290.
   PubMed Web of Science ®Google Scholar
• Al Subaie A, Emami E, Tamimi I, Laurenti M, Eimar H, Abdallah M-N, Tamimi F. 2016. Systemic administration of omeprazole interferes with bone healing and implant osseointegration: an in vivo study on rat tibiae. J Clin Periodontol. 43:193–203.
   PubMed Web of Science ®Google Scholar
• Albrektsson T, Brånemark P-I, Hansson H-A, Kasemo B, Larsson K, Lundström I, McQueen DH, Skalak R. 1983. The interface zone of inorganic implants in vivo: titanium implants in bone. Ann Biomed Eng. 11:1–27.
   Web of Science ®Google Scholar
• Apostu D, Lucaciu O, Lucaciu GDO, Crisan B, Crisan L, Baciut M, Onisor F, Baciut G, Câmpian RS, Bran S. 2017. Systemic drugs that influence titanium implant osseointegration. Drug Metab Rev. 49:92–104.
   PubMed Web of Science ®Google Scholar
• Benea HRC, Earar K, Lattanzi W, Quercia V. 2018. Collagen scaffold and lipoaspirate fluid-derived stem cells for the treatment of cartilage defects in a rabbit model. Rev Chim. 69:515–520.
   Web of Science ®Google Scholar
• Benea H, Tomoaia G, Soritau O, Pasca R-D. 2016. A review on the reconstruction of articular cartilage using collagen scaffolds. Rom Biotechnol Lett. 21:11735–11743.
   Web of Science ®Google Scholar
• Berglundh T, Abrahamsson I, Lang NP, Lindhe J. 2003. De novo alveolar bone formation adjacent to endosseous implants. Clin Oral Implants Res. 14:251–262.
   PubMed Web of Science ®Google Scholar
• Bonsignore LA, Anderson JR, Lee Z, Goldberg VM, Greenfield EM. 2013. Adherent lipopolysaccharide inhibits the osseointegration of orthopedic implants by impairing osteoblast differentiation. Bone. 52:93–101.
   PubMed Web of Science ®Google Scholar
• Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E. 2017. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study. Osteoporos Int. 28:1587–1595.
   PubMed Web of Science ®Google Scholar
• Buchholz HW, Elson RA, Engelbrecht E, Lodenkämper H, Röttger J, Siegel A. 1981. Management of deep infection of total hip replacement. J Bone Joint Surg Br. 63-B:342–353.
   PubMedGoogle Scholar
• Cai D, Feng W, Jiang Q. 2015. Acid-suppressive medications and risk of fracture: an updated meta-analysis. Int J Clin Exp Med. 8:8893–8904.
   PubMed Web of Science ®Google Scholar
• Cea Soriano L, Ruigomez A, Johansson S, Garcia Rodriguez LA. 2014. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy. 34:570–581.
   PubMed Web of Science ®Google Scholar
• Chrcanovic BR, Kisch J, Albrektsson T, Wennerberg A. 2017. Intake of proton pump inhibitors is associated with an increased risk of dental implant failure. Int J Oral Maxillofac Implants. 32:1097–1102.
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Zhao W, Quesenberry C. 2010. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 139:93–101.
   PubMed Web of Science ®Google Scholar
• Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH. 2013. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J. 280:5052–5064.
   PubMed Web of Science ®Google Scholar
• Cottrell JA, Vales FM, Schachter D, Wadsworth S, Gundlapalli R, Kapadia R, O'Connor JP. 2010. Osteogenic activity of locally applied small molecule drugs in a rat femur defect model. J Biomed Biotechnol. 2010:1.
   Google Scholar
• Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. 2008. The cell biology of bone metabolism. J Clin Pathol. 61:577–587.
   PubMed Web of Science ®Google Scholar
• Delomenede M, Buchet R, Mebarek S. 2009. Lansoprazole is an uncompetitive inhibitor of tissue-nonspecific alkaline phosphatase. Acta Biochim Pol. 56:301–305.
   PubMed Web of Science ®Google Scholar
• Ding J, Heller DA, Ahern FM, Brown TV. 2014. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int. 94:597–607.
   PubMed Web of Science ®Google Scholar
• Dobrowolski P, Tomaszewska E, Radzki RP, Bienko M, Wydrych J, Zdybel A, Pierzynowski SG. 2013. Can 2-oxoglutarate prevent changes in bone evoked by omeprazole? Nutrition. 29:556–561.
   PubMed Web of Science ®Google Scholar
• Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. 2011. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 9:257–267.
   PubMed Web of Science ®Google Scholar
• Fock KM, Ang TL, Bee LC, Lee E. 2008. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 47:1–6.
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Haynes K, Denburg MR, Zemel BS, Leonard MB, Abrams JA, Yang Y-X. 2015. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 26:2501–2507.
   PubMed Web of Science ®Google Scholar
• Gould E, Clements C, Reed A, Giori L, Steiner JM, Lidbury JA, Suchodolski JS, Brand M, Moyers T, Emery L, et al. 2016. A prospective, placebo‐controlled pilot evaluation of the effect of omeprazole on serum calcium, magnesium, cobalamin, gastrin concentrations, and bone in cats. J Vet Intern Med. 30:779–786.
   PubMed Web of Science ®Google Scholar
• Hadjidakis DJ, Androulakis II. 2006. Bone remodeling. Ann N Y Acad Sci. 1092:385–396.
   PubMed Web of Science ®Google Scholar
• Hasanin AH. 2014. Impact of omeprazole on bone remodeling in normal and ovariectomized Wistar rats. Eur Rev Med Pharmacol Sci. 18:1948–1956.
   PubMed Web of Science ®Google Scholar
• Hernandez RK, Do TP, Critchlow CW, Dent RE, Jick SS. 2012. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthop. 83:653–660.
   PubMed Web of Science ®Google Scholar
• Histing T, Stenger D, Scheuer C, Metzger W, Garcia P, Holstein JH, Klein M, Pohlemann T, Menger MD. 2012. Pantoprazole, a proton pump inhibitor, delays fracture healing in mice. Calcif Tissue Int. 90:507–514.
   PubMed Web of Science ®Google Scholar
• Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. 2010. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 56:112–116.
   PubMed Web of Science ®Google Scholar
• Hyun JJ, Chun HJ, Keum B, Seo YS, Kim YS, Jeen YT, Lee HS, Um SH, Kim CD, Ryu HS, et al. 2010. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 26:877–883.
   PubMed Web of Science ®Google Scholar
• Ito T, Jensen RT. 2010. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 12:448–457.
   PubMedGoogle Scholar
• Joo MK, Park J-J, Lee BJ, Kim JH, Yeon JE, Kim JS, Byun KS, Bak Y-T. 2013. The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats. Mol Med Rep. 7:1267–1272.
   PubMed Web of Science ®Google Scholar
• Kaye JA, Jick H. 2008. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 28:951–959.
   PubMed Web of Science ®Google Scholar
• Khalili H, Huang ES, Jacobson BC, Camargo CA, Feskanich D, Chan AT. 2012. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 344:e372.
   PubMed Web of Science ®Google Scholar
• Kwok CS, Yeong JK, Loke YK. 2011. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 48:768–776.
   PubMed Web of Science ®Google Scholar
• Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, Prince RL. 2014. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res. 29:2489–2497.
   PubMed Web of Science ®Google Scholar
• Lucaciu O, Campian RS, Soritau O, et al. 2018. Dental follicle stem cell as a biomaterial for periodontal regeneration a proof-of-concept study. Rev Chim. 69:1785–1790.
   Google Scholar
• Lucaciu O, Soriţău O, Gheban D, Ciuca DR, Virtic O, Vulpoi A, Dirzu N, Câmpian R, Băciuţ G, Popa C, et al. 2015. Dental follicle stem cells in bone regeneration on titanium implants. BMC Biotechnol. 15:114.
   PubMed Web of Science ®Google Scholar
• Matuszewska A, Nowak B, Rzeszutko M, Zduniak K, Szandruk M, Jędrzejuk D, Landwójtowicz M, Bolanowski M, Pieśniewska M, Kwiatkowska J, et al. 2016. Effects of long-term administration of pantoprazole on bone mineral density in young male rats. Pharmacol Rep. 68:1060–1064.
   PubMed Web of Science ®Google Scholar
• Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. 2011. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 106:1209–1218.
   PubMed Web of Science ®Google Scholar
• O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. 2005. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 118:778–781.
   PubMed Web of Science ®Google Scholar
• Parithimarkalaignan S, Padmanabhan TV. 2013. Osseointegration: an update. J Indian Prosthodont Soc. 13:2–6.
   PubMedGoogle Scholar
• Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, de Boer A, van Staa T, de Vries F. 2011. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 22:903–910.
   PubMed Web of Science ®Google Scholar
• Prause M, Seeliger C, Unger M, van Griensven M, Haug AT. 2014. Pantoprazole increases cell viability and function of primary human osteoblasts in vitro. Injury. 45:1156–1164.
   PubMed Web of Science ®Google Scholar
• Prause M, Seeliger C, Unger M, Rosado Balmayor E, van Griensven M, Haug AT. 2015. Pantoprazole decreases cell viability and function of human osteoclasts in vitro. Mediators Inflamm. 2015:413097.
   PubMed Web of Science ®Google Scholar
• Puleo DA, Nanci A. 1999. Understanding and controlling the bone-implant interface. Biomaterials. 20:2311–2321.
   PubMed Web of Science ®Google Scholar
• Reyes C, Formiga F, Coderch M, Hoyo J, Ferriz G, Casanovas J, Monteserín R, Brotons C, Rojas M, Moral I, et al. 2013. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone. 52:557–561.
   PubMed Web of Science ®Google Scholar
• Roberts S, Narisawa S, Harmey D, Millan JL, Farquharson C. 2007. Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization. J Bone Miner Res. 22:617–627.
   PubMed Web of Science ®Google Scholar
• Rostom A, Dube C, Wells G, et al. 2002. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. (4):CD002296.
   PubMedGoogle Scholar
• Salai M, Somjen D, Gigi R, Yakobson O, Katzburg S, Dolkart O. 2013. Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study. Bone Joint J. 95-B:1575–1580.
   PubMed Web of Science ®Google Scholar
• Savarino V, Dulbecco P, Savarino E. 2016. Are proton pump inhibitors really so dangerous? Dig Liver Dis. 48:851–859.
   PubMedGoogle Scholar
• Sheraly AR, Lickorish D, Sarraf F, Davies JE. 2009. Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv. 6:192–198.
   PubMedGoogle Scholar
• Shi S, Klotz U. 2008. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 64:935–951.
   PubMed Web of Science ®Google Scholar
• Shin JM, Kim N. 2013. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 19:25–35.
   PubMed Web of Science ®Google Scholar
• Singh R, Trickett R, Meyer C, Lewthwaite S, Ford D. 2016. Prophylactic proton pump inhibitors in femoral neck fracture patients - A life - and cost-saving intervention. Ann R Coll Surg. 98:371–375.
   PubMed Web of Science ®Google Scholar
• Sostres C, Gargallo CJ, Arroyo MT, Lanas A. 2010. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 24:121–132.
   PubMed Web of Science ®Google Scholar
• Su B, O’Connor JP. 2013. NSAID therapy effects on healing of bone, tendon, and the enthesis. J Appl Physiol. 115:892–899.
   PubMed Web of Science ®Google Scholar
• Takasugi S, Shioyama M, Kitade M, Nagata M, Yamaji T. 2016. Effects of proton pump inhibitor administration and intake of a combination of yogurt and galactooligosaccharides on bone and mineral metabolism in rats. Nutrients. 8:653.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Lix LM, Leung S, Leslie WD. 2010. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 138:896–904.
   PubMed Web of Science ®Google Scholar
• Thaler HW, Sterke CS, van der Cammen TJ. 2016. Association of proton pump inhibitor use with recurrent falls and risk of fractures in older women: a study of medication use in older fallers. J Nutr Health Aging. 20:77–81.
   PubMed Web of Science ®Google Scholar
• Tilinca MC, Pal S, Preg Z, Barabas-Hajdu E. 2018. The relationship of metabolic and endocrine parameters with associated diseases in diabetes mellitus. Rev Chim. 69:1288–1291.
   Web of Science ®Google Scholar
• Tuukkanen J, Vaananen H. 1986. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 38:123–125.
   PubMed Web of Science ®Google Scholar
• Vakil N. 2012. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 72:437–445.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. 2006. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 79:76–83.
   PubMed Web of Science ®Google Scholar
• Wang L, Li M, Cao Y, Han Z, Wang X, Atkinson EJ, Liu H, Amin S. 2017. proton pump inhibitors and the risk for fracture at specific sites: data mining of the FDA adverse event reporting system. Sci Rep. 7:5527.
   PubMed Web of Science ®Google Scholar
• Wu X, Al-Abedalla K, Abi-Nader S, Daniel NG, Nicolau B, Tamimi F. 2017. Proton pump inhibitors and the risk of osseointegrated dental implant failure: a cohort study. Clin Implant Dent Relat Res. 19:222–232.
   PubMed Web of Science ®Google Scholar
• Yanagihara GR, de Paiva AG, Neto MP, Torres LH, Shimano AC, Louzada MJQ, Annoni R, de Oliveira Penoni ÁC. 2015. Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone. Rev Bras Ortop. 50:232–238.
   PubMedGoogle Scholar
• Yang YX, Lewis JD, Epstein S, Metz DC. 2006. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 296:2947–2953.
   PubMed Web of Science ®Google Scholar
• Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, Zhang X, He J. 2011. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 23:794–800.
   PubMed Web of Science ®Google Scholar
• Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC. 2008. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 83:251–259.
   PubMed Web of Science ®Google Scholar
• Zaidi M. 1990. Modularity of osteoclast behaviour and ‘mode-specific’ inhibition of osteoclast function. Biosci Rep. 10:547–556.
   PubMed Web of Science ®Google Scholar
• Zhou B, Huang Y, Li H, Sun W, Liu J. 2016. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 27:339–347.
   PubMed Web of Science ®Google Scholar